Latest Regulatory Milestones News

Brazilian Critical Minerals (ASX: BCM) has locked in pre-approval under Australia’s R&D Tax Incentive for its Ema Rare Earth Project, including critical overseas activities in Brazil. This reduces regulatory uncertainty and supports funding efficiency for advancing the project’s development.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Sinowin Lithium, MRG Metals’ JV partner, will fund drilling at Corridor North in Mozambique, extending its investment beyond the 2 billion tonne Corridor Central and South projects targeting 2027 production and a ramp-up to 800,000 tonnes per annum.

RareX Limited has advanced its rare earths ambitions by securing a key mining lease at Cummins Range, appointing a strategic board member, and raising $5 million to fund exploration and development.

Comet Ridge progresses engineering design and environmental approvals for its Mahalo Gas Project, pushing ahead with the acquisition of Santos’ stake to consolidate full ownership and expand its east coast gas footprint.

ABx Group has made significant strides in its rare earths and clean fluorine chemical projects, receiving high-purity product validation and advancing pilot plant construction, while progressing bauxite mining approvals across multiple states.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Boab Metals has secured a A$236 million syndicated loan and final regulatory approvals, accelerating construction at its Sorby Hills Silver-Lead-Zinc Project with production on track for H2 2027.

Finder Energy has secured A$27 million via a two-tranche placement plus a A$3 million share purchase plan to fast-track its KTJ oil project in Timor-Leste, aiming for final investment decision by mid-2026 and first oil by late 2027.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.